Boehringer merges cancer vaccine and oncolytic virus teams; Dantari sells off assets
Plus, news about Madrona and Abdera:
Boehringer Ingelheim combines two cancer units: The drugmaker is merging its cancer vaccine unit AMAL Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.